Subjects treated, or anticipated to be treated, with a calcineurin inhibitor (because concomitant use of sirolimus and a calcineurin inhibitor increases the risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy [HUS/TTP/TMA]).
Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP)
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura
Platelet >= ,/mm^ (unless impairment due to idiopathic thrombocytopenic purpura [ITP])
Autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP) that is uncontrolled or requires > mg daily (QD) of prednisone (or equivalent) to maintain hemoglobin >. g/dL or platelets >, ?L without transfusion support
Uncontrolled autoimmune hemolytic anemia (Hgb < g/deciliter) or idiopathic thrombocytopenic purpura (< ,/l)
History of autoimmune disorder (e.g. hepatitis; idiopathic thrombocytopenic purpura [ITP]; scleroderma; severe psoriasis affecting > % of the body, rheumatoid arthritis requiring more than intermittent nonsteroidal anti-inflammatory drugs [NSAID] for management)
Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
Patients with active or uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP) are excluded; patients who have transfusion-dependent thrombocytopenia or bleeding/coagulation disorders that may increase the risk of life-threatening bleeding are excluded
Autoimmune disease with the exception of controlled/treated hypothyroidism, disease-related immune thrombocytopenic purpura, or hemolytic anemia
Autoimmune disease related to CLL, e.g., idiopathic thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, is permitted if not requiring active treatment
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura
History of thrombotic microangiopathy, hemolytic-uremic syndrome, or thrombotic thrombocytopenic purpura
Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP) that is uncontrolled or requiring >  mg once daily (QD) of prednisone (or equivalent) to maintain hemoglobin > . g/dL or platelets > , ?L without transfusion support
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura.
Active, uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)
Uncontrolled autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia purpura (ITP)
Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions (within  year of first dose)
History of microangiopathic hemolysis, thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS)
Underlying renal disease with a high risk of disease recurrence in the transplanted kidney, including:\r\n* Focal segmental glomerulosclerosis (FSGS)\r\n* Type I or II membranoproliferative glomerulonephritis\r\n* Hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura
Subjects enrolled into the previously untreated subject cohort must also meet all of the following criteria: No prior treatment for CLL (prior corticosteroid immunosuppression treatment for autoimmune hemolytic anaemia and idiopathic thrombocytopenic purpura (ITP) is permitted); Be considered inappropriate for fludarabine-based therapy for reasons that include, but are not limited to, advanced age or presence of co-morbidities.
Active autoimmune hemolytic anaemia (AIHA) and idiopathic thrombocytopenic purpura (ITP) requiring corticosteroid therapy greater than  mg prednisone (or equivalent) or chemotherapy.
Active, uncontrolled autoimmune phenomenon autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (AIHA, ITP) requiring steroid therapy
Presently with or a history of acute promyelocytic leukemia (APML), idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic uremic syndrome (HUS)
History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura
Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP)